*Correspondence: Dan Li, [email protected] These authors have contributed equally to this work and share first authorship Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Availability of data and materials Data supporting the findings of this study are available from the corresponding author upon reasonable request by a qualified researcher and upon approval by the data-clearing committee of the Medical University Vienna
While all state Medicaid programs cover GLP-1 agonists for type 2 diabetes, its much less common for them to cover the drugs for obesity
In practice, the optimal dose schedule likely varies by body weight, metabolic baseline, genetic factors, and individual receptor sensitivity
(Retrieved 12 July 2018.) "The Strange Saga of Kowloon Walled City" Atlas Obscura